1	Tissue	tissue	_	_	_	_	_	_	_
2	factor	factor	_	_	_	_	_	_	_
3	expression	expression	_	_	_	_	_	_	_
4	of	of	_	_	_	_	_	_	_
5	human	human	_	_	_	_	_	_	_
6	monocytes	monocyte	_	_	_	_	_	_	_
7	is	be	_	_	_	_	_	_	_
8	suppressed	suppress	_	_	_	_	_	_	_
9	by	by	_	_	_	_	_	_	_
10	lysophosphatidylcholine	lysophosphatidylcholine	_	_	_	_	_	_	_
11	.	.	_	_	_	_	_	_	_

1	The	the	_	_	_	_	_	_	_
2	expression	expression	_	_	_	_	_	_	_
3	of	of	_	_	_	_	_	_	_
4	tissue	tissue	_	_	_	_	_	_	_
5	factor	factor	_	_	_	_	_	_	_
6	(	(	_	_	_	_	_	_	_
7	TF	TF	_	_	_	_	_	_	_
8	)	)	_	_	_	_	_	_	_
9	,	,	_	_	_	_	_	_	_
10	the	the	_	_	_	_	_	_	_
11	principal	principal	_	_	_	_	_	_	_
12	initiator	initiator	_	_	_	_	_	_	_
13	of	of	_	_	_	_	_	_	_
14	coagulation	coagulation	_	_	_	_	_	_	_
15	,	,	_	_	_	_	_	_	_
16	is	be	_	_	_	_	_	_	_
17	increased	increase	_	_	_	_	_	_	_
18	during	during	_	_	_	_	_	_	_
19	inflammation	inflammation	_	_	_	_	_	_	_
20	and	and	_	_	_	_	_	_	_
21	atherosclerosis	atherosclerosis	_	_	_	_	_	_	_
22	.	.	_	_	_	_	_	_	_

1	Both	both	_	_	_	_	_	_	_
2	conditions	condition	_	_	_	_	_	_	_
3	are	be	_	_	_	_	_	_	_
4	promoted	promote	_	_	_	_	_	_	_
5	by	by	_	_	_	_	_	_	_
6	lysophosphatidylcholine	lysophosphatidylcholine	_	_	_	_	_	_	_
7	(	(	_	_	_	_	_	_	_
8	lysoPC	lysopc	_	_	_	_	_	_	_
9	)	)	_	_	_	_	_	_	_
10	.	.	_	_	_	_	_	_	_

1	We	we	_	_	_	_	_	_	_
2	observed	observe	_	_	_	_	_	_	_
3	in	in	_	_	_	_	_	_	_
4	the	the	_	_	_	_	_	_	_
5	present	present	_	_	_	_	_	_	_
6	study	study	_	_	_	_	_	_	_
7	that	that	_	_	_	_	_	_	_
8	lysoPC	lysopc	_	_	_	_	_	_	_
9	(	(	_	_	_	_	_	_	_
10	1	1	_	_	_	_	_	_	_
11	to	to	_	_	_	_	_	_	_
12	10	10	_	_	_	_	_	_	_
13	micromol/L	micromol/l	_	_	_	_	_	_	_
14	)	)	_	_	_	_	_	_	_
15	dose-dependently	dose-dependently	_	_	_	_	_	_	_
16	reduced	reduce	_	_	_	_	_	_	_
17	TF	TF	_	_	_	_	_	_	_
18	activity	activity	_	_	_	_	_	_	_
19	in	in	_	_	_	_	_	_	_
20	human	human	_	_	_	_	_	_	_
21	monocytes	monocyte	_	_	_	_	_	_	_
22	,	,	_	_	_	_	_	_	_
23	as	as	_	_	_	_	_	_	_
24	elicited	elicit	_	_	_	_	_	_	_
25	by	by	_	_	_	_	_	_	_
26	lipopolysaccharide	lipopolysaccharide	_	_	_	_	_	_	_
27	(	(	_	_	_	_	_	_	_
28	LPS).	LPS).	_	_	_	_	_	_	_
29	Lysophosphatidylethanolamine	Lysophosphatidylethanolamine	_	_	_	_	_	_	_
30	(	(	_	_	_	_	_	_	_
31	lysoPE	lysoPE	_	_	_	_	_	_	_
32	)	)	_	_	_	_	_	_	_
33	and	and	_	_	_	_	_	_	_
34	other	other	_	_	_	_	_	_	_
35	lysophospholipids	lysophospholipid	_	_	_	_	_	_	_
36	did	do	_	_	_	_	_	_	_
37	not	not	_	_	_	_	_	_	_
38	affect	affect	_	_	_	_	_	_	_
39	LPS-induced	lps-induced	_	_	_	_	_	_	_
40	TF	tf	_	_	_	_	_	_	_
41	activity	activity	_	_	_	_	_	_	_
42	of	of	_	_	_	_	_	_	_
43	human	human	_	_	_	_	_	_	_
44	monocytes	monocyte	_	_	_	_	_	_	_
45	.	.	_	_	_	_	_	_	_

1	TF	TF	_	_	_	_	_	_	_
2	antigen	antigen	_	_	_	_	_	_	_
3	expression	expression	_	_	_	_	_	_	_
4	as	as	_	_	_	_	_	_	_
5	elicited	elicit	_	_	_	_	_	_	_
6	by	by	_	_	_	_	_	_	_
7	LPS	LPS	_	_	_	_	_	_	_
8	was	be	_	_	_	_	_	_	_
9	also	also	_	_	_	_	_	_	_
10	lowered	lower	_	_	_	_	_	_	_
11	by	by	_	_	_	_	_	_	_
12	lysoPC	lysopc	_	_	_	_	_	_	_
13	.	.	_	_	_	_	_	_	_

1	Phospholipid	Phospholipid	_	_	_	_	_	_	_
2	analyses	analysis	_	_	_	_	_	_	_
3	indicated	indicate	_	_	_	_	_	_	_
4	a	a	_	_	_	_	_	_	_
5	selective	selective	_	_	_	_	_	_	_
6	increase	increase	_	_	_	_	_	_	_
7	in	in	_	_	_	_	_	_	_
8	the	the	_	_	_	_	_	_	_
9	lysoPC	lysopc	_	_	_	_	_	_	_
10	content	content	_	_	_	_	_	_	_
11	of	of	_	_	_	_	_	_	_
12	the	the	_	_	_	_	_	_	_
13	monocytes	monocyte	_	_	_	_	_	_	_
14	after	after	_	_	_	_	_	_	_
15	preincubation	preincubation	_	_	_	_	_	_	_
16	with	with	_	_	_	_	_	_	_
17	the	the	_	_	_	_	_	_	_
18	lysophospholipid	lysophospholipid	_	_	_	_	_	_	_
19	.	.	_	_	_	_	_	_	_

1	LysoPC	LysoPC	_	_	_	_	_	_	_
2	inhibited	inhibit	_	_	_	_	_	_	_
3	the	the	_	_	_	_	_	_	_
4	TF	TF	_	_	_	_	_	_	_
5	activity	activity	_	_	_	_	_	_	_
6	of	of	_	_	_	_	_	_	_
7	Mono	Mono	_	_	_	_	_	_	_
8	Mac-6	Mac-6	_	_	_	_	_	_	_
9	cells	cell	_	_	_	_	_	_	_
10	to	to	_	_	_	_	_	_	_
11	a	a	_	_	_	_	_	_	_
12	similar	similar	_	_	_	_	_	_	_
13	extent	extent	_	_	_	_	_	_	_
14	as	as	_	_	_	_	_	_	_
15	in	in	_	_	_	_	_	_	_
16	the	the	_	_	_	_	_	_	_
17	monocytes	monocyte	_	_	_	_	_	_	_
18	.	.	_	_	_	_	_	_	_

1	LPS	lps	_	_	_	_	_	_	_
2	binding	binding	_	_	_	_	_	_	_
3	to	to	_	_	_	_	_	_	_
4	plasma	plasma	_	_	_	_	_	_	_
5	membrane	membrane	_	_	_	_	_	_	_
6	receptors	receptor	_	_	_	_	_	_	_
7	and	and	_	_	_	_	_	_	_
8	internalization	internalization	_	_	_	_	_	_	_
9	of	of	_	_	_	_	_	_	_
10	LPS	lps	_	_	_	_	_	_	_
11	into	into	_	_	_	_	_	_	_
12	monocytes	monocyte	_	_	_	_	_	_	_
13	were	be	_	_	_	_	_	_	_
14	not	not	_	_	_	_	_	_	_
15	affected	affect	_	_	_	_	_	_	_
16	by	by	_	_	_	_	_	_	_
17	lysoPC	lysopc	_	_	_	_	_	_	_
18	.	.	_	_	_	_	_	_	_

1	In	in	_	_	_	_	_	_	_
2	contrast	contrast	_	_	_	_	_	_	_
3	,	,	_	_	_	_	_	_	_
4	LPS-mediated	lps-mediated	_	_	_	_	_	_	_
5	nuclear	nuclear	_	_	_	_	_	_	_
6	binding	binding	_	_	_	_	_	_	_
7	of	of	_	_	_	_	_	_	_
8	nuclear	nuclear	_	_	_	_	_	_	_
9	factor-kappaB/Rel	factor-kappab/rel	_	_	_	_	_	_	_
10	to	to	_	_	_	_	_	_	_
11	a	a	_	_	_	_	_	_	_
12	TF-specific	tf-specific	_	_	_	_	_	_	_
13	kappaB	kappab	_	_	_	_	_	_	_
14	site	site	_	_	_	_	_	_	_
15	was	be	_	_	_	_	_	_	_
16	inhibited	inhibit	_	_	_	_	_	_	_
17	by	by	_	_	_	_	_	_	_
18	lysoPC	lysopc	_	_	_	_	_	_	_
19	.	.	_	_	_	_	_	_	_

1	Induction	Induction	_	_	_	_	_	_	_
2	of	of	_	_	_	_	_	_	_
3	TF	TF	_	_	_	_	_	_	_
4	mRNA	mrna	_	_	_	_	_	_	_
5	expression	expression	_	_	_	_	_	_	_
6	by	by	_	_	_	_	_	_	_
7	LPS	LPS	_	_	_	_	_	_	_
8	tended	tend	_	_	_	_	_	_	_
9	to	to	_	_	_	_	_	_	_
10	be	be	_	_	_	_	_	_	_
11	partially	partially	_	_	_	_	_	_	_
12	reduced	reduce	_	_	_	_	_	_	_
13	by	by	_	_	_	_	_	_	_
14	the	the	_	_	_	_	_	_	_
15	lysophospholipid	lysophospholipid	_	_	_	_	_	_	_
16	.	.	_	_	_	_	_	_	_

1	Preincubation	preincubation	_	_	_	_	_	_	_
2	with	with	_	_	_	_	_	_	_
3	lysoPC	lysopc	_	_	_	_	_	_	_
4	increased	increase	_	_	_	_	_	_	_
5	monocytic	monocytic	_	_	_	_	_	_	_
6	cAMP	camp	_	_	_	_	_	_	_
7	levels	level	_	_	_	_	_	_	_
8	.	.	_	_	_	_	_	_	_

1	Inhibition	Inhibition	_	_	_	_	_	_	_
2	of	of	_	_	_	_	_	_	_
3	adenylyl	adenylyl	_	_	_	_	_	_	_
4	cyclase	cyclase	_	_	_	_	_	_	_
5	by	by	_	_	_	_	_	_	_
6	pretreatment	pretreatment	_	_	_	_	_	_	_
7	with	with	_	_	_	_	_	_	_
8	2’-deoxy-3’-adenosine	2'-deoxy-3'-adenosine	_	_	_	_	_	_	_
9	monophosphate	monophosphate	_	_	_	_	_	_	_
10	partially	partially	_	_	_	_	_	_	_
11	reversed	reverse	_	_	_	_	_	_	_
12	the	the	_	_	_	_	_	_	_
13	inhibition	inhibition	_	_	_	_	_	_	_
14	of	of	_	_	_	_	_	_	_
15	TF	TF	_	_	_	_	_	_	_
16	activity	activity	_	_	_	_	_	_	_
17	promoted	promote	_	_	_	_	_	_	_
18	by	by	_	_	_	_	_	_	_
19	lysoPC	lysopc	_	_	_	_	_	_	_
20	.	.	_	_	_	_	_	_	_

1	In	in	_	_	_	_	_	_	_
2	conclusion	conclusion	_	_	_	_	_	_	_
3	,	,	_	_	_	_	_	_	_
4	lysoPC	lysopc	_	_	_	_	_	_	_
5	markedly	markedly	_	_	_	_	_	_	_
6	decreases	decrease	_	_	_	_	_	_	_
7	LPS-mediated	lps-mediated	_	_	_	_	_	_	_
8	TF	TF	_	_	_	_	_	_	_
9	expression	expression	_	_	_	_	_	_	_
10	of	of	_	_	_	_	_	_	_
11	human	human	_	_	_	_	_	_	_
12	monocytes	monocyte	_	_	_	_	_	_	_
13	,	,	_	_	_	_	_	_	_
14	the	the	_	_	_	_	_	_	_
15	effect	effect	_	_	_	_	_	_	_
16	probably	probably	_	_	_	_	_	_	_
17	being	be	_	_	_	_	_	_	_
18	mediated	mediate	_	_	_	_	_	_	_
19	by	by	_	_	_	_	_	_	_
20	both	both	_	_	_	_	_	_	_
21	transcriptional	transcriptional	_	_	_	_	_	_	_
22	and	and	_	_	_	_	_	_	_
23	posttranscriptional	posttranscriptional	_	_	_	_	_	_	_
24	mechanisms	mechanism	_	_	_	_	_	_	_
25	.	.	_	_	_	_	_	_	_

1	LysoPC	LysoPC	_	_	_	_	_	_	_
2	may	may	_	_	_	_	_	_	_
3	thus	thus	_	_	_	_	_	_	_
4	attenuate	attenuate	_	_	_	_	_	_	_
5	activation	activation	_	_	_	_	_	_	_
6	of	of	_	_	_	_	_	_	_
7	coagulation	coagulation	_	_	_	_	_	_	_
8	during	during	_	_	_	_	_	_	_
9	inflammation	inflammation	_	_	_	_	_	_	_
10	and	and	_	_	_	_	_	_	_
11	atherosclerosis	atherosclerosis	_	_	_	_	_	_	_
12	.	.	_	_	_	_	_	_	_

